上消化道肠球菌属微生物群失调是胰腺癌手术患者死亡的危险因素
这项前瞻性生物标志物研究在德国单中心纳入101例胰腺头切除术患者,采用16S rRNA测序和微生物培养分析消化道及手术部位微生物定植。结果显示,胰十二指肠腺癌患者胆道肠球菌属存在与围术期感染及术后和长期死亡率升高相关,支持哌拉西林-他唑巴坦作为围术期抗生素预防。
要点
- 胰腺癌患者胆汁中肠球菌属存在与严重手术部位感染及24个月死亡率升高相关。
- 上消化道肠球菌相对丰度升高与6个月死亡率相关。
- 术前ERCP与胆汁中粪肠球菌共存时PDAC患者死亡率最高。
核心结论
- PDAC患者胆道肠球菌属存在是围术期感染及术后和长期死亡率升高的重要危险因素。
- 该发现支持既往数据中哌拉西林-他唑巴坦作为胰十二指肠切除术围术期抗生素预防的适宜选择。
研究设计与样本
- 前瞻性生物标志物研究,在德国单中心高容量胰腺中心进行。
- 共纳入101例患者,包括38例非癌症患者和63例癌症患者(其中50例胰腺导管腺癌患者)。
- 采用16S rRNA测序和微生物培养,采集消化道各部位及手术部位样本。
- 第一系列数据分析利用96例患者的16S rRNA测序数据评估微生物组与临床参数及结局的关联。
- 第二步聚焦术中胆汁抽吸液的微生物培养,分析其与围术期并发症和长期生存的关联。
主要发现
- 微生物组成随采样部位、癌症、年龄或术前内镜逆行胰胆管造影干预而变化,尤其胆汁微生物组。
- 在PDAC亚组中,胆汁或壶腹周围微生物组的组成变异与术后并发症如重症监护室入住显著相关。
- 在分类学水平上,发生深部或器官腔隙手术部位感染的患者中肠球菌属显著更丰富。
- 上消化道肠球菌相对丰度升高与6个月死亡率相关。
- 癌症患者胆汁标本中肠球菌属是与严重手术部位感染相关的最常见致病共生菌分离株之一,并与高达24个月的死亡率升高相关。
临床怎么用
- 作者认为,PDAC患者胆道肠球菌属存在是围术期感染及术后和长期死亡率升高的重要危险因素。
- 作者指出,该发现支持既往数据中哌拉西林-他唑巴坦作为胰十二指肠切除术围术期抗生素预防的适宜选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent retrospective studies suggest a role for distinct microbiota in the perioperative morbidity and mortality of pancreatic head resections. OBJECTIVE: We aimed to prospectively investigate the microbial colonization of critical operative sites of pancreatic head resections to identify microbial stratification factors for surgical and long-term oncologic outcomes. METHODS: Prospective biomarker study applying 16S rRNA sequencing and microbial culturing to samples collected from various sites of the gastrointestinal tract and surgical sites of patients during pancreatic head resections at a German single high-volume pancreatic center. RESULTS: A total of 101 patients were included {38 noncancer, 63 cancer patients [50 pancreatic ductal adenocarcinoma (PDAC) patients]} in the study. In a first data analysis series, 16S rRNA sequencing data were utilized from 96 patients to assess associations of microbiome profiles with clinical parameters and outcomes. In general, microbiome composition varied according to sampling site, cancer, age or preoperative endoscopic retrograde cholangiopancreatography (ERCP) intervention, notably for the bile microbiome. In the PDAC subcohort, the compositional variance of the bile or periampullary microbiome was significantly associated with postoperative complications such as intensive care unit admission; on a taxonomic level we observed Enterococcus spp. to be significantly more abundant in patients developing deep or organ-space surgical site infections (SSI). Elevated Enterococcus relative abundances in the upper gastrointestinal tract, in turn, were associated with 6 months mortality rates. In a second step, we focused on microbiological cultures collected from bile aspirates during surgery and investigated associations with perioperative complications and long-term survival. Notably, Enterococcus spp. were among the most prevalent pathobiont isolates observed in cancer patient bile specimens that were associated with severe SSIs, and thereby elevated mortality rates up to 24 months. Clinically relevant postoperative pancreatic fistulas or severe SSI were found as other major variables determining short-term mortality in this cancer patient cohort. In the context of adverse microbiological factors, a preoperative ERCP was also observed to segregate long-term survival, and it appeared to interact with the presence of Enterococcus spp. as highest mortality rates were observed in PDAC patients with both preoperative ERCP and presence of E. faecalis in bile aspirates. CONCLUSIONS: The presence of Enterococcus spp. in bile ducts of PDAC patients undergoing pancreatic surgery represents a significant risk factor for perioperative infections and, thereby, elevated postoperative and long-term mortality. This finding supports previous data on the use of the antibiotic drug piperacillin-tazobactam as appropriate perioperative antibiotic prophylaxis for preventing adverse outcomes after pancreatoduodenectomy.
引用
- Stein-Thoeringer CK, Renz BW, De Castilhos J, et al. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreatic Cancer. Ann Surg. 2024. PMID: 38275104. doi:10.1097/SLA.0000000000006210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。